Stock HEM HEMOSTEMIX INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hemostemix Inc.

Equities

HEM

CA4236943060

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 09:30:00 2024-05-23 am EDT 		5-day change 1st Jan Change
0.04 CAD 0.00% Intraday chart for Hemostemix Inc. 0.00% -42.86%
Apr. 30 Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 06 Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 24.07 1.504 32.46 9.464 13.63 6.099
Enterprise Value (EV) 1 22.6 3.545 32.38 10.73 17.62 10.26
P/E ratio -3.86 x - -2.91 x -1.46 x -2.41 x -2.31 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA - -755,079 x -6,639,112 x -1,611,863 x -5,384,372 x -4,399,167 x
EV / FCF -12.8 x -2.15 x -20 x -10.5 x -4.62 x -8.35 x
FCF Yield -7.83% -46.4% -5.01% -9.48% -21.7% -12%
Price to Book 49.3 x - -35.4 x -1.79 x -2.01 x -0.83 x
Nbr of stocks (in thousands) 15,045 15,045 46,369 59,151 75,743 87,122
Reference price 2 1.600 - 0.7000 0.1600 0.1800 0.0700
Announcement Date 4/30/19 7/10/20 4/30/21 5/3/22 5/1/23 4/29/24
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA - -4.694 -4.876 -6.655 -3.273 -2.333
EBIT 1 -6.423 -4.696 -4.879 -6.656 -3.274 -2.334
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -6.181 -4.87 -7.768 -6.542 -4.749 -2.502
Net income 1 -6.188 -4.87 -7.768 -6.286 -5.235 -2.502
Net margin - - - - - -
EPS 2 -0.4144 -0.3237 -0.2410 -0.1094 -0.0748 -0.0303
Free Cash Flow 1 -1.771 -1.646 -1.622 -1.017 -3.818 -1.23
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/30/19 7/10/20 4/30/21 5/3/22 5/1/23 4/29/24
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 2.04 - 1.26 3.99 4.17
Net Cash position 1 1.47 - 0.08 - - -
Leverage (Debt/EBITDA) - -0.4346 x - -0.1897 x -1.219 x -1.785 x
Free Cash Flow 1 -1.77 -1.65 -1.62 -1.02 -3.82 -1.23
ROE (net income / shareholders' equity) -232% 274% 302% 197% 86.9% 35.4%
ROA (Net income/ Total Assets) -115% -332% -251% -288% -398% -374%
Assets 1 5.368 1.465 3.092 2.181 1.316 0.6683
Book Value Per Share 2 0.0300 -0.2700 -0.0200 -0.0900 -0.0900 -0.0800
Cash Flow per Share 2 0.1000 0 0 0 0 0
Capex - 0.01 - - - -
Capex / Sales - - - - - -
Announcement Date 4/30/19 7/10/20 4/30/21 5/3/22 5/1/23 4/29/24
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
HEMOSTEMIX INC. Stock Hemostemix Inc.
-42.86% 2.54M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+10.79% 116B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.65% 106B
BIONTECH SE Stock BioNTech SE
-6.20% 23.89B
ARGENX SE Stock argenx SE
-3.17% 21.58B
GENMAB A/S Stock Genmab A/S
-10.79% 18.96B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.41% 16.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.50% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.64% 14.14B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+31.84% 12.02B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. HEM Stock
  4. Financials Hemostemix Inc.